ERBB2 and gastric cancer: Pembrolizumab, which combines trastuzumab with chemotherapy drugs like fluoropyrimidine or platinum in the first-line treatment of locally advanced, unresectable, or metastatic HER-2-positive gastric cancer, has been expedited approved by the U.S. Food and Drug Administration (FDA) depended on the findings of this study.